Candida auris is an emerging species of yeast characterized by colonization of skin, persistence in the healthcare environment, and antifungal resistance. C. auris was first described in 2009 from a single isolate but has since been reported in more than 25 countries worldwide. Resistance to fluconazole and amphotericin B is common, and resistance to the echinocandins is emerging in some countries. Antifungal resistance has been shown to be acquired rather than intrinsic and the primary mechanisms of resistance to the echinocandins and azoles have been determined. There are a number of new antifungal agents in phase 2 and phase 3 clinical trials and many have activity against C. auris. This review will discuss what is currently known about antifungal resistance in C. auris, limitations to antifungal susceptibility testing, the mechanisms of resistance, and the new antifungals that are on the horizon.

黄金假丝酵母是一种新兴的酵母菌，其特征是皮肤定植，在医疗环境中持久存在以及抗真菌能力强。2009年首次描述了金黄色葡萄球菌的单一分离株，但此后在全球25个以上国家进行了报道。对氟康唑和两性霉素B的耐药性很普遍，并且在某些国家/地区对耐棘球菌素的耐药性正在上升。已证明获得的是抗真菌抗药性，而不是内在的抗真菌药，并且已经确定了对棘手and蛋白和唑类药物具有抗药性的主要机理。在2期和3期临床试验中有许多新的抗真菌药，而且许多药对耳尾梭菌具有活性。这篇评论将讨论目前关于抗真菌药的已知信息C. auris，抗真菌药敏试验的局限性，耐药性机制以及即将出现的新抗真菌药。